These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 23149332)

  • 1. Impact of diabetes mellitus on vessel response in the drug-eluting stent era: pooled volumetric intravascular ultrasound analyses.
    Sakata K; Waseda K; Kume T; Otake H; Nakatani D; Yock PG; Fitzgerald PJ; Honda Y
    Circ Cardiovasc Interv; 2012 Dec; 5(6):763-71. PubMed ID: 23149332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
    JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of vascular response to zotarolimus-eluting stent vs paclitaxel-eluting stent implantation: pooled IVUS results from the ZoMaxx I and II trials.
    Waseda K; Hasegawa T; Ako J; Honda Y; Grube E; Whitbourn R; Ormiston J; O'Shaughnessy CD; Henry TD; Overlie P; Schwartz LB; Sudhir K; Chevalier B; Gray WA; Yeung AC; Fitzgerald PJ;
    Circ J; 2010 Nov; 74(11):2334-9. PubMed ID: 20890052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of vascular response to the everolimus-eluting stent versus the paclitaxel-eluting stent: intravascular ultrasound results from the SPIRIT III trial.
    Yamasaki M; Tsujino I; Lima-Filho MO; Ako J; Shimohama T; Hasegawa T; Sakurai R; Sudhir K; Stone GW; Waseda K; Honda Y; Fitzgerald PJ
    EuroIntervention; 2012 Oct; 8(6):724-31. PubMed ID: 23086791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.
    Poerner TC; Otto S; Gassdorf J; Nitsche K; Janiak F; Scheller B; Goebel B; Jung C; Figulla HR
    Circ Cardiovasc Interv; 2014 Dec; 7(6):760-7. PubMed ID: 25371536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravascular ultrasound analysis of small vessel lesions treated with the Sparrow coronary stent system: results of the CARE II trial.
    Kume T; Waseda K; Koo BK; Yock PG; Botelho R; Verheye S; Whitbourn R; Meredith I; Worthley S; Hai KT; Honda Y; Abizaid A; Fitzgerald PJ
    Catheter Cardiovasc Interv; 2014 Jan; 83(1):19-24. PubMed ID: 23413202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intimal hyperplasia and vascular remodeling after everolimus-eluting and sirolimus-eluting stent implantation in diabetic patients: the randomized Diabetes and Drug-Eluting Stent (DiabeDES) IV Intravascular Ultrasound trial.
    Antonsen L; Maeng M; Thayssen P; Christiansen EH; Hansen KN; Kaltoft A; Hansen HS; Thuesen L; Lassen JF; Jensen LO
    Catheter Cardiovasc Interv; 2014 May; 83(6):864-72. PubMed ID: 23996918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial.
    Windecker S; Haude M; Neumann FJ; Stangl K; Witzenbichler B; Slagboom T; Sabaté M; Goicolea J; Barragan P; Cook S; Piot C; Richardt G; Merkely B; Schneider H; Bilger J; Erne P; Waksman R; Zaugg S; Jüni P; Lefèvre T
    Circ Cardiovasc Interv; 2015 Feb; 8(2):e001441. PubMed ID: 25634905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
    Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiographic and intravascular ultrasound follow up of paclitaxel- and sirolimus-eluting stent after poststent high-pressure balloon dilation: from the poststent optimal stent expansion trial.
    Park SM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y; Kang WC; Ahn T; Kim BK; Oh SJ; Jeon DW; Yang JY
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):15-21. PubMed ID: 20928842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neointimal response to second-generation drug-eluting stents in diabetic patients with de-novo coronary lesions: intravascular ultrasound study.
    Won H; Kang TS; Hong BK; Lee S; Jeon DW; Ryu SK; Min PK; Yoon YW; Lee BK; Kwon HM; Ko YG; Jang Y
    Coron Artery Dis; 2015 May; 26(3):212-9. PubMed ID: 25426659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
    Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial.
    Claessen BE; Henriques JPS; Vendrik J; Boerlage-van Dijk K; van der Schaaf RJ; Meuwissen M; van Royen N; Gosselink ATM; van Wely MH; Dirkali A; Arkenbout EK; Piek JJ; Baan J
    Catheter Cardiovasc Interv; 2019 Feb; 93(2):216-221. PubMed ID: 30232824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of bifurcation lesions treated with novel drug-eluting dedicated bifurcation stent system: intravascular ultrasound results of the AXXESS PLUS trial.
    Miyazawa A; Ako J; Hassan A; Hasegawa T; Abizaid A; Verheye S; McClean D; Neumann FJ; Grube E; Honda Y; Fitzgerald PJ
    Catheter Cardiovasc Interv; 2007 Dec; 70(7):952-7. PubMed ID: 18044777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III trials.
    Bartorelli AL; Serruys PW; Miquel-Hébert K; Yu S; Pierson W; Stone GW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):60-6. PubMed ID: 20578194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.